MMG Introduces Enhanced Education Platform for Clinical Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
MMG Introduces Enhanced Education Platform for Clinical Trials

Source: Applied Clinical Trials

MMG, a global health communications company specializing in clinical trial patient recruitment and retention, announced an exclusive strategic partnership with online healthcare communications company MedRespond to introduce Custom Conversations, its new technological advancement in clinical trial patient education.

Custom Conversations uses video, natural language query capabilities, and the Internet to allow people exploring clinical trial options to have a more customized online learning interaction. An advanced synthetic interview technology developed by Carnegie Mellon University, allows people to also can ask questions in their own words, and then receive pre-recorded video responses which have been pre-approved by the study’s institutional review board or ethics committee.

According to MMG, pilot programs have shown clear boosts in enrollment rates compared to trials for which patients received only traditional study educational materials.
The Custom Conversations platform can be also be leveraged throughout the study education continuum – from first learning about a study, to pre-qualification and screening, and for the duration of the study, which can help to fortify retention. Sponsors receive insight into the anonymous activity data to get a view into patients’ and caregivers’ communication needs and mindsets, which can be used to refine recruitment and retention strategies and messaging.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here